F2G Names CFO
F2G Ltd., a UK-based antifungal drug discovery and development company, has appointed Ralf Schmid chief financial officer. Schmid carries 20 years’ experience to F2G and joins the company from Nabriva Therapeutics AG, where he was chief financial officer and chief operating officer. He also held senior positions in finance and administration at various multinational companies including Sandoz.
You may also be interested in...
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.